UK +44 (0)1865 849841
Malaysia +60 3 2117 5193
  • Bridging The Policy-Practice Divide In Genome-Editing For Agriculture

    Regulation of emerging technology such as genome editing has mainly focused on responding to the consequences of innovation.

  • Four challenges in developing AI algorithms for medical imaging

    With so much emerging on the scene and the inherent technical challenges involved in extracting data from images, what we really want to be focusing on is this question: how robust and reliable is the application itself?

  • The top 4 challenges for microbiome companies – NIZO

    Microbiome research is abundant and profoundly inspiring. But despite the promise, companies in the field face challenges.

  • How do we build the solutions that will transform healthcare’s future?

    We are building the solutions that will revolutionise healthcare in the future: solutions that will transform the trust relationship between the industry and patients.

Pixel analysis: the new era of digital pathology

Professor David Snead is leading the implementation of digital pathology for Coventry and Warwickshire Pathology Services and directs one of the five Government funded centres in the UK pioneering AI and image diagnostics integration. His main research interests lie in extending the capability of digital pathology for routine diagnostic use and the advancement and deployment of computer assisted diagnostic algorithms. In this third highlight from the conference we revisit Professor Snead’s presentation to get a clinical perspective on how deep learning and artificial intelligence (AI) are set to play an increasing role in daily practice.

Read More

New sourcing of natural ingredients for cosmeceuticals

The sourcing of natural plant-based compounds is becoming a worldwide bottleneck. The Greenhouse Pharmacy programme of Wageningen University & Research builds new chains between high-tech horticulture and cosmeceutical companies for reliable sourcing of pesticide-free natural plant compounds.

Read More

A regulatory roadmap for the commercialization of microbial products for agriculture

A major paradigm shift in agricultural production is required to meet the demands of a global world population projected to reach 9.7 billion in 2050. We have to increase crop productivity sustainably while preserving biodiversity, natural resources, and grower income in the context of climate change. To optimize sustainable productivity and profitability on farms, grasslands, and forests, scientists and growers must embrace a holistic, systems-level approach and focus on the complexity within phytobiomes.

Read More

Unleashing the power of digital pathology and AI for precision medicine

We’re looking back at the highlights from the Digital Pathology and AI meeting in 2018 as we anticipate this year’s Digital Pathology and AI Congress in December. This second post in our mini-series reviews Marylin Bui’s keynote presentation where she explained how the combination of Digital Pathology and Artificial Intelligence (AI) holds huge potential for patient care.

Read More

Will the intersection of blockchain and AI inspire the Pharma R&D Renaissance?

Global Engage spoke to Scott Kahn ahead of the 3rdGlobal Pharma R&D Informatics and AI Congress. Scott is the CIO of Luna PBC, the entity that manages LunaDNA: a community-owned data-sharing resource. Their conversation was recorded as a podcast, which can be found here.

This is the second half of that conversation, where Scott discusses the challenges of distributive ledger technologies such as Blockchain, and their intersection with AI for Pharma R&D.

Read More

Digital Pathology and Deep Learning: AI assisting in PD-L1 scoring

Ahead of this year’s Digital Pathology and AI Congress in December we look back at some of the highlights from last year.

First up, Michel Vandenberghe’s presentation on a new deep learning algorithm, which demonstrates the potential of artificial Intelligence (AI) to support pathologists, has been developed for PD-L1 scoring in tumour cells and immune cells in urothelial carcinoma samples.

Read More

How to revolutionise clinical trials: engaging with participants as partners

Ahead of the 3rd Global Pharma R&D Informatics and AI Congress, Global Engage spoke to Scott Kahn, CIO of LunaPBC. LunaPBC is the company that manages LunaDNA: a community-owned data-sharing resource. Their conversation was recorded as a podcast, which can be found here.

In the first half of the conversation, Scott discusses the benefits of distributive ledger technologies such as Blockchain for Pharma R&D.

Read More

Falling off the cliff: are we short of pathologists?

I can recall clearly the pathologists coming to lecture our medical school class our second year in 1993.

Most of them felt compelled to tell us, “Pathology is a lot of fun, you can make a good living, but don’t go into it, there aren’t any jobs.”

Read More

Pixel analysis: the new era of digital pathology

Professor David Snead is leading the implementation of digital pathology for Coventry and Warwickshire Pathology Services and directs one of the five Government funded centres in the UK pioneering AI and image diagnostics integration. His main research interests lie in extending the capability of digital pathology for routine diagnostic use and the advancement and deployment of computer assisted diagnostic algorithms. In this third highlight from the conference we revisit Professor Snead’s presentation to get a clinical perspective on how deep learning and artificial intelligence (AI) are set to play an increasing role in daily practice.

Read More

New sourcing of natural ingredients for cosmeceuticals

The sourcing of natural plant-based compounds is becoming a worldwide bottleneck. The Greenhouse Pharmacy programme of Wageningen University & Research builds new chains between high-tech horticulture and cosmeceutical companies for reliable sourcing of pesticide-free natural plant compounds.

Read More

Unleashing the power of digital pathology and AI for precision medicine

We’re looking back at the highlights from the Digital Pathology and AI meeting in 2018 as we anticipate this year’s Digital Pathology and AI Congress in December. This second post in our mini-series reviews Marylin Bui’s keynote presentation where she explained how the combination of Digital Pathology and Artificial Intelligence (AI) holds huge potential for patient care.

Read More

Will the intersection of blockchain and AI inspire the Pharma R&D Renaissance?

Global Engage spoke to Scott Kahn ahead of the 3rdGlobal Pharma R&D Informatics and AI Congress. Scott is the CIO of Luna PBC, the entity that manages LunaDNA: a community-owned data-sharing resource. Their conversation was recorded as a podcast, which can be found here.

This is the second half of that conversation, where Scott discusses the challenges of distributive ledger technologies such as Blockchain, and their intersection with AI for Pharma R&D.

Read More

Digital Pathology and Deep Learning: AI assisting in PD-L1 scoring

Ahead of this year’s Digital Pathology and AI Congress in December we look back at some of the highlights from last year.

First up, Michel Vandenberghe’s presentation on a new deep learning algorithm, which demonstrates the potential of artificial Intelligence (AI) to support pathologists, has been developed for PD-L1 scoring in tumour cells and immune cells in urothelial carcinoma samples.

Read More

How to revolutionise clinical trials: engaging with participants as partners

Ahead of the 3rd Global Pharma R&D Informatics and AI Congress, Global Engage spoke to Scott Kahn, CIO of LunaPBC. LunaPBC is the company that manages LunaDNA: a community-owned data-sharing resource. Their conversation was recorded as a podcast, which can be found here.

In the first half of the conversation, Scott discusses the benefits of distributive ledger technologies such as Blockchain for Pharma R&D.

Read More

Falling off the cliff: are we short of pathologists?

I can recall clearly the pathologists coming to lecture our medical school class our second year in 1993.

Most of them felt compelled to tell us, “Pathology is a lot of fun, you can make a good living, but don’t go into it, there aren’t any jobs.”

Read More

Why drug designers will be at a disadvantage without AI

We spoke to John Griffin, CSO at Numerateto find out how AI is changing drug discovery and development. Numerate is a drug design company applying cutting-edge AI to transform the process of small molecule drug design.

Read More

A regulatory roadmap for the commercialization of microbial products for agriculture

A major paradigm shift in agricultural production is required to meet the demands of a global world population projected to reach 9.7 billion in 2050. We have to increase crop productivity sustainably while preserving biodiversity, natural resources, and grower income in the context of climate change. To optimize sustainable productivity and profitability on farms, grasslands, and forests, scientists and growers must embrace a holistic, systems-level approach and focus on the complexity within phytobiomes.

Read More

Slides from the Plant Genomics & Gene Editing Congress: Europe

The latest event in the Plant Genomics series provided two days of intriguing topics and case studies, not least concerning the ECJ ruling on gene editing and Machine Learning techniques in plant genomics. We have made the following presentation slides available from Ian Bancroft, Anna Coll, Aalt-Jan van Dijk, Nigel Halford, and Jurriaan Ton.

Read More

Microbial solutions to improve crop growth, crop protection, and crop yield

Gregory Maloney, Senior Scientist at Novozymes BioAg will be hosting a roundtable discussion at the Partnerships in Biocontrol, Biostimulants & Microbiome Congress: USA on navigating the regulatory landscape of biological product development. We spoke to him ahead of the congress about his work.

Read More

A new kind of pheromone to control agricultural pests

Karl Cameron Schiller is co-founder of Pheronym, a Davis-based agriculture biotech start-up using a new kind of pheromone from microscopic roundworms called nematodes to control agricultural pests. We asked him about his work.

Read More

Navigating the regulatory landscape for agricultural products

Terry Stone has worked in agricultural products for almost 30 years and has experience in both research and regulatory affairs. He is currently President, TB Stone Solutions. He was previously Vice President of Regulatory Affairs and Sustainability Programs for Agrinos, where he worked with industry associations in the US and the EU to develop a regulatory framework for plant biostimulants. We spoke to him about his work.

Read More

Excellence in Breeding: developing breeding programs in Africa and South Asia

Kelly Robbins is Assistant Professor at Cornell University. He started his career in animal breeding and later went on to work as a quantitative geneticist at a large private seed company. We spoke to him ahead of his presentation at the 7th Plant Genomics and Gene Editing Congress: USA.

I came to Cornell University as director of a large project funded by the Bill and Melinda Gates Foundation called the Genomic Open-Source Breeding Informatics Initiative (GOBII for short).

With the cost of sequencing rapidly declining, it seems inevitable that routine of genomic information in breeding programs in Africa and South Asia will become more prevalent. However, there are certain capabilities, tools, and technologies that need to be in place to be able to exploit this type of information effectively and use it to drive higher rates of genetic gains.

Read More

Improving crop production through understanding the soil microbiome

Sarah Strauss is a soil microbial ecologist at the University of Florida. Her interests lie in understanding the interactions between soil microbes and crops, with the hope that improved understanding will benefit crop production.

We spoke to her about her work ahead of her presentation at the 4th Partnerships in Biocontrol, Biostimulants & Microbiome Congress: USA.

The interactions between soil microbes and plants are still very much uncharted territory, which makes it an exciting area of study. This is especially the case for the interactions between soil microbes and crops in agricultural systems. For example, we know that there are bacteria and fungi that can influence plant growth or soil nutrient availability, but most of those studies have been done with only a few plant species or under very specific growing conditions. Much of my research is looking at what interactions are occurring between specific crops in field conditions – and how those interactions might differ based on specific conditions or crops in a farmer’s field.

Read More

The Plant Genomics and Gene Editing Congress Presentation Slides

Following the Plant Genomics and Gene Editing Congress: Europe, we have made the following presentation slides from Ana Atanassova, Ian Bancroft, Nigel Halford and Kim Hammond-Kossack available.

Read More

Examining Blockchain Systems & Designing Smart Contracts

The blockchain has the potential to enable the collaboration between patients, researchers, and care providers to provide individualised care for patients, but how can this technology be harnessed in a practical way?

This was one of the key questions that was asked at the Blockchain in Healthcare Congress and we had the pleasure of welcoming an array of expert speakers from pharma, academia, and industry to provide the answer.

Read More

The role of extrinsic motivation in sports and physical activity

Motivation is one of the most significant psychological concepts in many areas of life – from work and education to achieving personal goals. In sports and physical activity, motivation plays an especially important part due to the fact that, to millions of people worldwide, staying fit and active is not an obligation or a professional prerequisite, but rather a personal goal. Blockchain technology, together with elements of gamification, may actually help people achieve this goal.

Read More

Conciliating Blockchain and GDPR

Aurélie Bayle is a Data Protection Officer at be-ys: a role she considers to be at the heart of the new legal framework for any company.

Before GDPR came into effect on 25th May 2018, she was working towards global compliance, which involved completing all the steps given by the Article 29 Data Protection Working Party, an advisory board made up of a representative from the data authority of each EU Member State, the European Data Protection Supervisor, and the European Commission. Her duties have included auditing the structures and processes, preparing the data protection impact assessments, checking the compliance of processing activities, analysing the risks of the processing in the medical area, preparing new processes and policies about data protection, and asking data processors about their own compliance.

Read More

When Blockchain Meets the Right to be Forgotten: Technology Versus Law

Over the past few years, the popularity of the blockchain and cryptocurrencies has increased and has reached important notoriety, not only in scientific and IT journals, but also in the media. Although there are many kinds of cryptocurrencies in circulation nowadays, the most popular is Bitcoin.

Read More

Supporting Blockchain Startups: An Open Letter from Katherine Merton

Dear colleagues,

The blockchain technology market is expected to grow to 2.3 billion US dollars by 2021, from 339.5 million US dollars in 2017. [1] With an annual growth rate of 61.5%, it is one of the fastest growing technologies in the healthcare industry.

Read More

The Big List of Microfluidics Companies & Investors

The microfluidic-based devices market has been growing since 2014 due to the increasing point of care testing demand and the miniaturisation of microfluidic chips. 

Read More

What will we do with all this data?

The amount of data we are creating every day has increased exponentially to match the rise in use of smart and connected devices. The internet of things has connected every aspect of our lives to the digital realm: most of these devices operate by tracking your habits, movements, preferences, voice, and more, then logging those habits online. Specifically, the collection of health data has become abundant, because most people now have or wear some sort of device to track daily patterns, steps, cycles, and more. Even our phones often default to track these things for us, whether we choose to enable the function or not.

Read More

How Standards & Standardised Infrastructure Fuel Innovation

It might surprise a lot of people to learn that standards can be viewed as a tool to support innovation, to set businesses free and to focus on the core of their product where their expertise lie. When working with the use of electronic communication systems within the entire healthcare sector, the main focal point is often ensuring a good support for collaboration and work processes.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive